BRPI0912249A2 - método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada. - Google Patents

método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.

Info

Publication number: BRPI0912249A2
Authority: BR; Brazil
Prior art keywords: arthritis; individuals; development; preventing; undifferentiated
Prior art date: 2008-05-05

Application number

BRPI0912249A

Other languages

English (en)

Inventor

George Vratsanos

Jean-Claude Becker

Michael Corbo

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-05

Filing date

2009-05-05

Publication date

2015-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912249(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-05 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2015-10-20 Publication of BRPI0912249A2 publication Critical patent/BRPI0912249A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Plant Substances (AREA)
Saccharide Compounds (AREA)

BRPI0912249A 2008-05-05 2009-05-05 método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada. BRPI0912249A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5033608P	2008-05-05	2008-05-05
US12/387,359 US7915222B2 (en)	2008-05-05	2009-05-01	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en)	2008-05-05	2009-05-05	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number	Publication Date
BRPI0912249A2 true BRPI0912249A2 (pt)	2015-10-20

Family

ID=41264941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0912249A BRPI0912249A2 (pt)	2008-05-05	2009-05-05	método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.

Country Status (25)

Country	Link
US (3)	US7915222B2 (pt)
EP (2)	EP2279206B1 (pt)
JP (1)	JP2011522795A (pt)
KR (1)	KR20110014180A (pt)
CN (1)	CN102037010A (pt)
AR (1)	AR071672A1 (pt)
AU (1)	AU2009244448B2 (pt)
BR (1)	BRPI0912249A2 (pt)
CA (1)	CA2723698C (pt)
CL (1)	CL2009001082A1 (pt)
DK (1)	DK2279206T3 (pt)
EA (1)	EA201001749A1 (pt)
ES (1)	ES2539840T3 (pt)
HK (1)	HK1208230A1 (pt)
HR (1)	HRP20150552T1 (pt)
HU (1)	HUE025256T2 (pt)
IL (1)	IL208691A (pt)
MX (1)	MX2010011503A (pt)
NZ (1)	NZ589020A (pt)
PL (1)	PL2279206T3 (pt)
PT (1)	PT2279206E (pt)
SI (1)	SI2279206T1 (pt)
TW (2)	TW201444575A (pt)
WO (1)	WO2009137424A1 (pt)
ZA (1)	ZA201007914B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040022787A1 (en) *	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) *	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN103906767A (zh) *	2011-10-10	2014-07-02	米迪缪尼有限公司	对类风湿关节炎的治疗
US20140006055A1 (en) *	2012-06-27	2014-01-02	Iagnosis, Inc.	Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) *	2012-10-30	2015-08-20	Emory University	Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) *	2013-03-15	2014-09-25	Bristol-Myers Squibb Company	Method of treating granulomatosis with polyangiitis
KR20160145789A (ko) *	2014-04-25	2016-12-20	브리스톨-마이어스 스큅 컴퍼니	초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도
JP2018512856A (ja)	2015-04-17	2018-05-24	アルパインイミューンサイエンシズインコーポレイテッド	調整可能な親和性を有する免疫調節タンパク質
KR20250020681A (ko)	2017-10-10	2025-02-11	알파인 이뮨 사이언시즈, 인코포레이티드	Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202006148UA (en)	2018-01-03	2020-07-29	Alpine Immune Sciences Inc	Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) *	2019-05-10	2023-07-04	中山大学孙逸仙纪念医院	一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6641809B1 (en) *	1990-03-26	2003-11-04	Bristol-Myers Squibb Company	Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) *	1990-03-26	2006-07-04	Bristol-Myers Squibb Company	Methods for blocking binding of CD28 receptor to B7
US6090914A (en) *	1991-06-27	2000-07-18	Bristol-Myers Squibb Company	CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) *	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE122007000078I2 (de) *	1991-06-27	2011-01-13	Bristol Myers Squibb Co	CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
CA2154487A1 (en) *	1993-01-21	1994-08-04	Nicholas S. Hill	Vaccines and methods for preventing and treating fescue toxicosis in herbivores
US5773253A (en) *	1993-01-22	1998-06-30	Bristol-Myers Squibb Company	MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) *	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997034633A1 (en) *	1996-03-20	1997-09-25	Bristol-Myers Squibb Company	Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) *	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
CA2411962A1 (en) *	2000-06-09	2001-12-20	Bristol-Myers Squibb Company	Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) *	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SK287940B6 (sk) *	2000-07-03	2012-05-03	Bristol-Myers Squibb Company	Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
AU2002243905B2 (en) *	2001-01-26	2007-11-08	Emory University	Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
MXPA03010568A (es) *	2001-05-23	2005-03-07	Squibb Bristol Myers Co	Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
PT1576182E (pt) *	2002-12-23	2011-01-21	Bristol Myers Squibb Co	Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas
JP4541157B2 (ja) *	2002-12-23	2010-09-08	ブリストル−マイヤーズスクイブカンパニー	タンパク質を製造するための哺乳類細胞培養法
NZ545314A (en) *	2003-08-04	2009-03-31	Bristol Myers Squibb Co	Methods for treating cardiovascular disease using a soluble CTLA4 molecule
DE602006020138D1 (de)	2005-06-29	2011-03-31	Compumedics Ltd	Sensoranordnung mit leitfähiger brücke
WO2007024964A1 (en) *	2005-08-22	2007-03-01	Incept, Llc	Flared stents and apparatus and methods for making and using them
NZ569108A (en)	2005-12-20	2011-09-30	Bristol Myers Squibb Co	Formulations of CTLA4Ig stabilised using sugars
KR101398713B1 (ko)	2005-12-20	2014-06-12	브리스톨-마이어스 스큅 컴퍼니	조성물 및 조성물의 제조 방법
US7528111B2 (en) *	2006-05-12	2009-05-05	Bristol-Myers Squibb Company	Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) *	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

2009
- 2009-05-01 US US12/387,359 patent/US7915222B2/en active Active
- 2009-05-05 ES ES09743410.4T patent/ES2539840T3/es active Active
- 2009-05-05 SI SI200931228T patent/SI2279206T1/sl unknown
- 2009-05-05 TW TW103129409A patent/TW201444575A/zh unknown
- 2009-05-05 MX MX2010011503A patent/MX2010011503A/es active IP Right Grant
- 2009-05-05 WO PCT/US2009/042761 patent/WO2009137424A1/en not_active Ceased
- 2009-05-05 EP EP20090743410 patent/EP2279206B1/en active Active
- 2009-05-05 NZ NZ589020A patent/NZ589020A/en not_active IP Right Cessation
- 2009-05-05 AU AU2009244448A patent/AU2009244448B2/en not_active Ceased
- 2009-05-05 DK DK09743410.4T patent/DK2279206T3/en active
- 2009-05-05 EA EA201001749A patent/EA201001749A1/ru unknown
- 2009-05-05 PL PL09743410T patent/PL2279206T3/pl unknown
- 2009-05-05 HR HRP20150552TT patent/HRP20150552T1/hr unknown
- 2009-05-05 CA CA2723698A patent/CA2723698C/en active Active
- 2009-05-05 CL CL2009001082A patent/CL2009001082A1/es unknown
- 2009-05-05 CN CN2009801162049A patent/CN102037010A/zh active Pending
- 2009-05-05 AR ARP090101621A patent/AR071672A1/es unknown
- 2009-05-05 JP JP2011508582A patent/JP2011522795A/ja active Pending
- 2009-05-05 PT PT97434104T patent/PT2279206E/pt unknown
- 2009-05-05 BR BRPI0912249A patent/BRPI0912249A2/pt not_active Application Discontinuation
- 2009-05-05 HU HUE09743410A patent/HUE025256T2/en unknown
- 2009-05-05 KR KR1020107027221A patent/KR20110014180A/ko not_active Ceased
- 2009-05-05 TW TW098114831A patent/TWI454278B/zh not_active IP Right Cessation
- 2009-05-05 EP EP15152246.3A patent/EP2891665A1/en not_active Withdrawn
2010
- 2010-10-13 IL IL208691A patent/IL208691A/en not_active IP Right Cessation
- 2010-11-04 ZA ZA2010/07914A patent/ZA201007914B/en unknown
2011
- 2011-02-10 US US13/024,601 patent/US8435952B2/en active Active
- 2011-03-07 HK HK15108768.6A patent/HK1208230A1/en unknown
2013
- 2013-03-27 US US13/851,166 patent/US9012408B2/en active Active

Also Published As

Publication number	Publication date
HUE025256T2 (en)	2016-02-29
EP2279206A1 (en)	2011-02-02
US20130195865A1 (en)	2013-08-01
TW201444575A (zh)	2014-12-01
AR071672A1 (es)	2010-07-07
NZ589020A (en)	2012-05-25
US8435952B2 (en)	2013-05-07
EA201001749A1 (ru)	2011-06-30
EP2279206B1 (en)	2015-04-22
ZA201007914B (en)	2011-07-27
AU2009244448B2 (en)	2014-07-31
HK1208230A1 (en)	2016-02-26
US20110142835A1 (en)	2011-06-16
PT2279206E (pt)	2015-07-27
PL2279206T3 (pl)	2015-09-30
CA2723698C (en)	2018-03-06
CN102037010A (zh)	2011-04-27
TWI454278B (zh)	2014-10-01
US20090280119A1 (en)	2009-11-12
CL2009001082A1 (es)	2010-02-12
ES2539840T3 (es)	2015-07-06
US7915222B2 (en)	2011-03-29
TW200948381A (en)	2009-12-01
CA2723698A1 (en)	2009-11-12
HK1148291A1 (en)	2011-09-02
IL208691A0 (en)	2010-12-30
EP2891665A1 (en)	2015-07-08
EP2279206A4 (en)	2011-05-25
US9012408B2 (en)	2015-04-21
SI2279206T1 (sl)	2015-08-31
HRP20150552T1 (hr)	2015-06-19
AU2009244448A1 (en)	2009-11-12
KR20110014180A (ko)	2011-02-10
MX2010011503A (es)	2010-11-09
JP2011522795A (ja)	2011-08-04
IL208691A (en)	2015-01-29
WO2009137424A1 (en)	2009-11-12
DK2279206T3 (en)	2015-07-27

Publication	Publication Date	Title
BRPI0912249A2 (pt)	2015-10-20	método de prevenir o desenvolvimento de artrite reumatoide em indivíduos com artrite não diferenciada.
BRPI0917120A2 (pt)	2015-11-17	método, e, meio legível por computador.
BRPI0922312A2 (pt)	2016-01-05	método, e, meio legível por computador
BRPI0818272A2 (pt)	2015-04-14	Antígeno associado com artrite reumatóide
BRPI0821334A2 (pt)	2018-12-04	método utilizável em um poço, e sistema utilizável com um poço.
BRPI0817475A2 (pt)	2017-05-16	meio legível por computador.
BRPI0810746A2 (pt)	2014-10-21	Dispositivos e sistemas de células de combustível e respectivos métodos de produção e de uso.
BRPI0914208A2 (pt)	2015-11-03	célula de eletrólise, e, método
NO20073935L (no)	2009-01-28	Tetningsarrangement, samt tilhorende fremgangsmate
BRPI0814467A2 (pt)	2015-01-20	Método, e, biocombustível
BRPI0813710A2 (pt)	2014-10-07	Enzimas que produzem acetil-coa em levedura
BRPI1015379A2 (pt)	2016-04-19	sistemas de cálculo biométrico e métodos
BRPI0913227A2 (pt)	2016-01-19	método, e objeto
EP2508487A4 (en)	2013-07-17	WASTEWATER PRETREATMENT METHOD AND EFFLUENT TREATMENT METHOD USING THE PRETREATMENT PROCESS
BRPI0814466A2 (pt)	2015-01-20	Método.
BRPI0919724A2 (pt)	2015-12-08	unidade de processamento, e , meio legível por computador
BRPI0913112A2 (pt)	2016-01-05	fluxímetro, e, método.
BRPI0920736A2 (pt)	2015-12-29	módulo de placa e método de fabricação do mesmo.
BRPI0813569A2 (pt)	2014-12-23	Método de inspeção.
IT1397197B1 (it)	2013-01-04	Veicolo battipista e relativo metodo di controllo.
BRPI0906438A2 (pt)	2015-07-14	Isolamento de conteúdo por meio de processos em uma aplicação
EP2314678A4 (en)	2012-11-28	MICRO-RNA ASSOCIATED WITH RHEUMATOID ARTHRITIS
DK2068922T3 (da)	2012-10-08	Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
BRPI0808218A2 (pt)	2019-09-24	simulador de corrosão e o método correspondente
IT1397194B1 (it)	2013-01-04	Veicolo battipista e relativo metodo di controllo.

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-02	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001
2021-08-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2022-03-29	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-07-12	B09B	Patent application refused [chapter 9.2 patent gazette]
2023-10-03	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.